When was Cellics founded?

Cellics was founded in 2014 and raised its 1st funding round 3 years after it was founded.

Where is Cellics located?

Cellics is headquartered in San Diego, United States. It is registered at San Diego, California.

How many employees does Cellics have?

As of Apr 30, 2026, the latest employee count at Cellics is 22.

Is Cellics a funded company?

Cellics is a funded company, having raised a total of $26M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 21, 2017.

When was the latest funding round of Cellics?

Cellics' latest funding was a $***** Grant (prize money) round on Oct 21, 2020, with participation from 1 investor. Its primary sector is Drug Delivery. In United States, the Drug Delivery sector has seen $84.1M in funding in 2026 to date.

Where does Cellics rank among its competitors?

Cellics ranks 56th amongst 1179 active competitors, of which 102 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Imbed Biosciences, which secured an undisclosed amount in Jan, 2026.

Who are the top competitors of Cellics?

Cellics' top competitors include WuXi AppTec, Imbed Biosciences and ANI Pharmaceuticals. Among them, Imbed Biosciences secured the most recent funding round in January, 2026.

Cellics - 2026 Company Profile, Team, Funding & Competitors

Cellics is a series B company based in San Diego (United States), founded in 2014 by Lili Xie and Liangfang Zhang. It operates as a Developing therapies for infectious diseases & autoimmune disorders using Nanosponge technology. Cellics has raised $26M in funding. The company has 1179 active competitors, including 102 funded and 155 that have exited. Its top competitors include companies like WuXi AppTec, Imbed Biosciences and ANI Pharmaceuticals.

Company Details

Cellics Therapeutics is a preclinical stage company, developing therapies for various diseases using cell membrane coating technology. The company's proprietary Nanosponge Technology is based on coating nanoparticles and nanomaterials with cellular membranes taken directly from cells. The company focuses on the development of red blood cell membrane (RBC) coated Nanosponges to develop therapies for infectious diseases, autoimmune disorders, anti-venom, and vaccines. The company claims that the nanocoated RBC membrane-coated particles would remove toxins and venoms from the bloodstream & divert them from attacking normal cells. The company has product pipeline of therapies for bacterial infections, autoimmune hemolytic anemia, malaria, anti-venam and MRSA vaccine.

Website: cellics.com
Email ID: *****@cellics.com
Phone Number: +1 **********
Part Of
Registered Address: San Diego, California

Key Metrics

Founded Year

2014

Location

San Diego, United States

Stage

Series B

Total Funding

$26M in 4 rounds

Latest Funding Round

Grant (prize money), Oct 21, 2020, $*****

Investors

CARB-X & 1 more

Ranked

56^th among 1179 active competitors

Employee Count

22 as on Apr 30, 2026

Similar Companies

Imbed Biosciences & 160 more

View Cellics' full profile

Cellics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CELLICS THERAPEUTICS INC CIN: 465220148 , United States, Active	Dec 31, 2013	-	21 (As on Dec 31, 2024)	-

Cellics has raised a total funding of $26M over 4 rounds. Its first funding round was on Apr 21, 2017. Its latest funding round was a Grant (prize money) round on Oct 21, 2020 for $*****. 1 investor participated in its latest round. Cellics has 2 institutional investors.

Here is the list of recent funding rounds of Cellics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 21, 2020	3870694	Grant (prize money)	9658337	3785365	4005221	3613241
Jun 08, 2020	2432343	Series B	2963935	6590141	8728145	9834972
Apr 20, 2018	2381221	Series A	6998135	4518778	9987896	5458108

Access funding benchmarks and valuations. Sign up today!

View details of Cellics's funding rounds and investors

The founders of Cellics are Lili Xie and Liangfang Zhang.

Here are the details of Cellics' key team members:

Lili Xie: Co-Founder & Director of Cellics.
Liangfang Zhang: Founder of Cellics.
Contact Info: 1 email address
Huiqing Zhu: CEO of Cellics.
Contact Info: 2 email addresses

View details of Cellics's Founder profiles and Board Members

Cellics' employee count trend

Cellics has 22 employees as of Apr 26. Here is Cellics's employee count trend over the years:

Uncover Cellics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cellics include WuXi AppTec, Imbed Biosciences and ANI Pharmaceuticals. Here is the list of Top 10 competitors of Cellics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	WuXi AppTec 2000, Shanghai (China), Public	Provider of CRO and CDMO services	$40M	Synergis Capital, HongShan & 27 others	79/100
2nd	Imbed Biosciences 2010, Madison (United States), Series C	Provider of nanotech-based wound care products	$34.3M	Niterra, MassChallenge & 7 others	68/100
3rd	ANI Pharmaceuticals 1996, Baudette (United States), Public	Manufacturer of pharmaceutical products, including extended-release capsules and immediate-release tablets	-	Ampersand Capital, US Bank & 4 others	64/100
4th	EVERSANA 2014, Milwaukee (United States), Funding Raised	Provider of consulting services for drug pricing access, reimbursement, and regulatory support	-	ACE & Company, North Sky Capital & 2 others	63/100
5th	Aptar 1992, Crystal Lake (United States), Public	Provider of regulatory support, brand differentiation, and prototyping services	-	Al Zayani Investments	63/100
6th	Ipsen 1929, Paris (France), Public	Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes	-	Digital Pharma Lab, PAI Partners & 2 others	62/100
7th	NanoSyrinx 2018, Coventry (United Kingdom), Series A	Developer of targeted intracellular delivery platform for biological molecules	$21.6M	M Ventures, Octopus Ventures & 15 others	61/100
8th	Eurofins Scientific 1987, Luxembourg (Luxembourg), Public	Provider of laboratory testing services and CRO contract research services	-	CDPQ, Holland Capital & 1 others	61/100
9th	Zuellig Pharma 1992, Singapore (Singapore), Funding Raised	Provider of clinical research, quality management, logistics, and clinical trial supply services	-	Temasek	61/100
10th	Precision Medicine Group 2012, Bethesda (United States), Late Stage	Provider of clinical research, development, and commercialization services for life sciences	$532M	TPG, Blackstone & 7 others	60/100
56th	Cellics 2014, San Diego (United States), Series B	Developing therapies for infectious diseases & autoimmune disorders using Nanosponge technology	$26M	CARB-X, Cash Capital	44/100